Want to see SE:ENZY full AI Analyst Report?
Top Page
Enzymatica AB
(ENZY)
Select Model
Select Model
Rating:44Neutral
Price Target:
kr2.00
▲(0.00% Upside)
Action:Reiterated
Date:10/17/26
The score is primarily held back by weak financial sustainability: large ongoing losses and consistently negative operating/free cash flow, despite healthy gross margins and low leverage. Technicals are mixed with some short-term improvement but a still-weak longer-term trend. Valuation is also constrained by negative earnings (negative P/E) and no provided dividend yield.
Positive Factors
Very Low Leverage
Very low leverage reduces financial risk and preserves flexibility because the company has limited debt-related obligations. This gives management more room to allocate resources toward product development, commercialization, or operational improvement without substantial interest or refinancing pressure.
Negative Factors
Persistent Deep Losses
Deep and persistent operating and net losses show that current gross profit is insufficient to support the company’s cost base. Continued losses can constrain investment, require corrective actions, and weaken the durability of the business model unless profitability improves materially.
Read all positive and negative factors
Positive Factors
Negative Factors
Very Low Leverage
Very low leverage reduces financial risk and preserves flexibility because the company has limited debt-related obligations. This gives management more room to allocate resources toward product development, commercialization, or operational improvement without substantial interest or refinancing pressure.
Read all positive factors
Enzymatica AB (ENZY) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr517.03M
Dividend YieldN/A
Average Volume (3M)97.08K
Price to Earnings (P/E)―
Beta (1Y)-0.07
Revenue Growth3.26%
EPS Growth16.82%
CountrySE
Employees18
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.19
Shares Outstanding242,735,100
10 Day Avg. Volume88,472
30 Day Avg. Volume97,081
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)3.71
Price to Sales (P/S)8.56
P/FCF Ratio-11.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.3
Revenue Forecast (FY)kr109.00M
Enzymatica AB Business Overview & Revenue Model
Company Description
Enzymatica AB, a life science company headquartered in Lund, Sweden, focuses on the development and sale of medical devices for infection-related illnesses. Founded in 2007, its primary offering is the ColdZyme mouth spray, designed to help preven...
Enzymatica AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
21
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 51.93M | 53.90M | 45.58M | 50.90M | 48.95M | 57.24M |
| Gross Profit | 29.96M | 33.13M | 30.72M | 31.86M | 28.45M | 33.35M |
| EBITDA | -45.39M | -46.81M | -45.62M | -41.12M | -59.97M | -38.19M |
| Net Income | -45.85M | -51.89M | -53.18M | -49.73M | -68.66M | -45.39M |
Balance Sheet | ||||||
| Total Assets | 124.63M | 141.98M | 195.22M | 125.91M | 174.41M | 157.04M |
| Cash, Cash Equivalents and Short-Term Investments | 13.14M | 33.13M | 75.21M | 8.37M | 50.69M | 31.62M |
| Total Debt | 14.17M | 1.02M | 2.20M | 18.08M | 22.32M | 2.60M |
| Total Liabilities | 26.42M | 17.80M | 18.86M | 49.30M | 48.12M | 32.07M |
| Stockholders Equity | 98.22M | 124.17M | 176.37M | 76.61M | 126.29M | 124.97M |
Cash Flow | ||||||
| Free Cash Flow | -18.11M | -41.20M | -60.90M | -41.02M | -68.28M | -42.00M |
| Operating Cash Flow | -29.54M | -40.97M | -60.51M | -40.29M | -64.57M | -35.87M |
| Investing Cash Flow | -334.00K | -231.00K | -393.00K | -730.00K | -3.72M | -6.13M |
| Financing Cash Flow | -2.31M | -789.00K | 127.65M | -1.39M | 87.37M | 49.53M |
Enzymatica AB Technical Analysis
Positive
2.00
Price Trends
1.86
Positive
2.02
Positive
2.19
Negative
Market Momentum
0.07
Negative
67.29
Neutral
85.65
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ENZY, the sentiment is Positive. The current price of 2 is above the 20-day moving average (MA) of 1.86, above the 50-day MA of 1.86, and below the 200-day MA of 2.19, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 67.29 is Neutral, neither overbought nor oversold. The STOCH value of 85.65 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ENZY.
Enzymatica AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | kr12.13B | 30.98 | 31.08% | 1.37% | 13.13% | 23.94% | |
58 Neutral | kr3.06B | 35.44 | 1.24% | 1.46% | 2.73% | 36.67% | |
58 Neutral | kr115.23M | 14.65 | ― | 1.34% | 3.50% | 58.41% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | kr1.97B | -76.50 | -22.38% | ― | 104.76% | 37.08% | |
44 Neutral | kr517.03M | -11.49 | ― | ― | 3.26% | 16.82% |
* General Sector Average
SE:ENZY
Enzymatica AB
2.13
0.13
6.50%
SE:BIOG.B
BioGaia AB
119.90
21.80
22.22%
SE:SECARE
Swedencare AB
19.14
-19.11
-49.96%
SE:NANEXA
Nanexa AB
10.32
8.42
442.02%
SE:NNH
New Nordic Healthbrands AB
18.60
-6.10
-24.69%
SE:NEWBRY
Newbury Pharmaceuticals AB
1.58
-0.62
-28.18%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.